Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
90.42
+0.18 (0.20%)
At close: May 6, 2026, 4:00 PM EDT
92.00
+1.58 (1.75%)
Pre-market: May 7, 2026, 8:04 AM EDT
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Dianthus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $121.17, which forecasts a 34.01% increase in the stock price over the next year. The lowest target is $65 and the highest is $200.
Price Target: $121.17 (+34.01%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 7 | 7 | 7 |
| Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $103 → $105 | Buy | Maintains | $103 → $105 | +16.12% | May 6, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates $98 | Buy | Initiates | $98 | +8.38% | Apr 9, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $135 | Buy | Initiates | $135 | +49.30% | Mar 19, 2026 |
| Wedbush | Wedbush | Buy Maintains $80 → $103 | Buy | Maintains | $80 → $103 | +13.91% | Mar 12, 2026 |
| Wedbush | Wedbush | Buy Maintains $55 → $80 | Buy | Maintains | $55 → $80 | -11.52% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
1.30M
from 2.04M
Decreased by -36.20%
Revenue Next Year
1.64M
from 1.30M
Increased by 26.56%
EPS This Year
-4.42
from -4.20
EPS Next Year
-4.94
from -4.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.2M | 6.3M | ||||||
| Avg | 1.3M | 1.6M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 106.3% | 385.0% | ||||||
| Avg | -36.2% | 26.6% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.80 | -2.92 | ||||||
| Avg | -4.42 | -4.94 | ||||||
| Low | -6.42 | -7.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.